Top Five CRO Signs Agreement with NewCardio
A top five CRO has signed a Master Services Agreement (MSA) with
"The adoption of QTinno by the clinical pharmacology units at this top five CRO will enable them to deliver quality TQT/QT studies with higher accuracy and lower intrinsic variability in a timely and cost-effective manner," says Vincent Renz, NewCardio's President and Chief Operating Officer, in a company press release.
By adding this software to its existing offerings, the CRO will also be able to "capture additional" revenue because it will be able to provide customers with more services, the press release reports.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025
- Generative AI Transforms Clinical Study Report Development
September 16th 2025